Dehbid Mina, Tahmasvand Raheleh, Tasharofi Marzieh, Shojaie Fatemeh, Aghamaali Mahmoudreza, Almasirad Ali, Salimi Mona
Department of Biology, Faculty of Science, University of Guilan, Rasht, I.R. Iran.
Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, I.R. Iran.
Res Pharm Sci. 2022 Dec 24;18(1):24-38. doi: 10.4103/1735-5362.363593. eCollection 2023 Feb.
Considering various studies implying anticancer activity of the hydrazone and oxamide derivatives through different mechanisms such as kinases and calpain inhibition, herein, we report the synthesis, characterization, and evaluation of the antiproliferative effect of a series of hydrazones bearing oxamide moiety compounds () against a panel of cancer cell lines to explore a novel and promising anticancer agent ().
Chemical structures of the synthesized compounds were confirmed by FTIR, H-NMR, C-NMR, and mass spectra. The antiproliferative activity and cell cycle progression of the target compound were investigated using the MTT assay and flow cytometry.
FINDINGS/RESULTS: Compound with 2-hydroxybenzylidene structure was found to have a significant anti-proliferative influence on MDA-MB-231 (human adenocarcinoma breast cancer) and 4T1 (mouse mammary tumor) cells as the model of triple-negative breast cancer, with the IC50-72h values of 7.73 ± 1.05 and 1.82 ± 1.14 μM, respectively. Following 72-h incubation with compound , it caused MDA-MB-231 cell death through G1/S cell cycle arrest at high concentrations (12 and 16 μM).
Conclusively, this study for the first time reports the anti-proliferative efficacy of compound possessing 2-hydroxyphenyl moiety, which may serve as a potent candidate in triple-negative breast cancer treatment.
鉴于多项研究表明腙和草酰胺衍生物通过激酶抑制和钙蛋白酶抑制等不同机制具有抗癌活性,在此,我们报告了一系列含有草酰胺部分的腙类化合物()对一组癌细胞系的合成、表征及抗增殖作用评估,以探索一种新型且有前景的抗癌剂()。
通过傅里叶变换红外光谱(FTIR)、氢核磁共振谱(H-NMR)、碳核磁共振谱(C-NMR)和质谱对合成化合物的化学结构进行确证。采用MTT法和流式细胞术研究目标化合物的抗增殖活性和细胞周期进程。
发现具有2-羟基苄叉结构的化合物对三阴乳腺癌模型MDA-MB-231(人乳腺腺癌)和4T1(小鼠乳腺肿瘤)细胞具有显著的抗增殖影响,其72小时半数抑制浓度(IC50)值分别为7.73±1.05和1.82±1.14μM。用化合物孵育72小时后,在高浓度(12和16μM)下它通过使MDA-MB-231细胞在G1/S期细胞周期阻滞而导致细胞死亡。
总之,本研究首次报道了具有2-羟基苯基部分的化合物的抗增殖功效,其可能成为三阴乳腺癌治疗中的一种有效候选药物。